Kaizhen Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kaizhen Wang has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Florian A. Karreth
H. Lee Moffitt Cancer Center and Research Institute
106 shared publications - Xiaonan Xu
H. Lee Moffitt Cancer Center and Research Institute
106 shared publications - Neel Jasani
Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
100 shared publications - Olga Vera
Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute
72 shared publications - Olivier Elemento
Cornell Joan Klein Jacobs Center for Precision Nutrition and Health, Cornell University, Ithaca, USA
42 shared publications Akanksha Verma
41 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
RNA-Bound MYBL2 Engages the Oncogenic Transcription Factors MAFG and FRA1 to Promote Melanoma Progression
Non-mutational mechanisms, including copy number alterations and transcription factor dysregulation, are critical drivers of melanoma progression. Here, we identify the transcription factor MYBL2 as a key oncogenic driver located on frequently amplified chromosome 20q. MYBL2 overexpression promoted transformation and correlated with poor survival, yet paradoxically, the transactivation function of MYBL2 was dispensable for oncogenic activity. Instead, MYBL2 acquired a non-canonical RNA-binding function enabled by the melanoma-associated RNA landscape. Through these RNA interactions, MYBL2 reshaped the chromatin landscape toward an AP-1-permissive state and promoted chromatin association of the oncogenic transcription factors MAFG and FRA1, indirectly reprogramming tumor-promoting gene networks that predict poor outcomes across multiple cancers. Importantly, a decoy RNA that disrupts the MYBL2-RNA interaction impaired MYBL2 association with MAFG and FRA1 and suppressed melanoma cell growth. These findings establish MYBL2 as an RNA-binding-dependent, 20q gain-associated driver that promotes melanoma progression through chromatin and transcriptional network remodeling.
- 13 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Research
Open AccessRNA-Bound MYBL2 Engages the Oncogenic Transcription Factors MAFG and FRA1 to Promote Melanoma Progression
Non-mutational mechanisms, including copy number alterations and transcription factor dysregulation, are critical drivers of melanoma progression. Here, we identify the transcription factor MYBL2 as a key oncogenic driver located on frequently amplified chromosome 20q. MYBL2 overexpression promoted transformation and correlated with poor survival, yet paradoxically, the transactivation function of MYBL2 was dispensable for oncogenic activity. Instead, MYBL2 acquired a non-canonical RNA-binding function enabled by the melanoma-associated RNA landscape. Through these RNA interactions, MYBL2 reshaped the chromatin landscape toward an AP-1-permissive state and promoted chromatin association of the oncogenic transcription factors MAFG and FRA1, indirectly reprogramming tumor-promoting gene networks that predict poor outcomes across multiple cancers. Importantly, a decoy RNA that disrupts the MYBL2-RNA interaction impaired MYBL2 association with MAFG and FRA1 and suppressed melanoma cell growth. These findings establish MYBL2 as an RNA-binding-dependent, 20q gain-associated driver that promotes melanoma progression through chromatin and transcriptional network remodeling.
- Open Access
- 4 October 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (6)
Allele‐Specific GNAQ Q209 Mutations Reveal Context‐Dependent Oncogenic Programs in Uveal Melanoma
Uveal melanoma (UM) is driven by activating GNAQ/GNA11 mutations, predominantly at the hotspot Q209 residue. However, the functional impact of distinct GNAQ Q209 substitutions on downstream signaling and malignant progression remains unclear. Using immune‐competent, multistep UM mouse models combining eye‐restricted mutant GNAQ with BAP1 loss and MYC activation, we directly compared GNAQ Q209L and GNAQ Q209R in an otherwise matched genetic context. Tumors arising from either allele shared similar histology and cell‐state composition. However, GNAQ Q209L tumors progressed faster and were associated with reduced survival. In contrast, GNAQ Q209R tumor‐derived cell lines exhibited greater ex vivo fitness (proliferation, clonogenicity, and migration), whereas GNAQ Q209L ‐derived lines were relatively fragile in 2D culture. At the molecular level, GNAQ Q209R tumors preferentially engaged the FAK‐YAP axis in primary lesions and derived cell lines. Together, these results support an allele‐dependent, context‐specific trade‐off in which higher output GNAQ Q209L favors rapid in vivo expansion, while GNAQ Q209R promotes adaptability, potentially via FAK‐YAP signaling, nominating allele‐stratified therapeutic opportunities.
- 4 October 2026
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (6)
Open AccessAllele‐Specific GNAQ Q209 Mutations Reveal Context‐Dependent Oncogenic Programs in Uveal Melanoma
Uveal melanoma (UM) is driven by activating GNAQ/GNA11 mutations, predominantly at the hotspot Q209 residue. However, the functional impact of distinct GNAQ Q209 substitutions on downstream signaling and malignant progression remains unclear. Using immune‐competent, multistep UM mouse models combining eye‐restricted mutant GNAQ with BAP1 loss and MYC activation, we directly compared GNAQ Q209L and GNAQ Q209R in an otherwise matched genetic context. Tumors arising from either allele shared similar histology and cell‐state composition. However, GNAQ Q209L tumors progressed faster and were associated with reduced survival. In contrast, GNAQ Q209R tumor‐derived cell lines exhibited greater ex vivo fitness (proliferation, clonogenicity, and migration), whereas GNAQ Q209L ‐derived lines were relatively fragile in 2D culture. At the molecular level, GNAQ Q209R tumors preferentially engaged the FAK‐YAP axis in primary lesions and derived cell lines. Together, these results support an allele‐dependent, context‐specific trade‐off in which higher output GNAQ Q209L favors rapid in vivo expansion, while GNAQ Q209R promotes adaptability, potentially via FAK‐YAP signaling, nominating allele‐stratified therapeutic opportunities.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Phenotype of GnaqCA; Bap1CKO; MycCKI mice
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Phenotype of GnaqCA; Bap1CKO; MycCKI mice
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
ScRNA-seq characterization of murine UM composition
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
ScRNA-seq characterization of murine UM composition
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Predominant Melanocytic state and T-cell exhaustion in early UM tumors
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Predominant Melanocytic state and T-cell exhaustion in early UM tumors
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Data from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Uveal melanoma is a highly aggressive intraocular malignancy with limited therapeutic options for metastatic disease. Existing transgenic uveal melanoma mouse models inadequately recapitulate human disease progression, whereas transplant models lack immune competence for studying the tumor immune microenvironment and therapeutic interventions. To address these limitations, we developed a genetically engineered mouse model incorporating stepwise genetic alterations implicated in human uveal melanoma progression. Spatiotemporally controlled expression of mutant GNAQQ209L from the endogenous locus induced choroidal nevi with limited penetrance. Concomitant BAP1 deletion enhanced nevus formation, whereas further MYC activation led to fully penetrant intraocular tumors with the potential to disseminate. Single-cell RNA sequencing revealed that malignant cells segregated into melanocytic and neural crest–like subpopulations characterized by distinct transcriptional and biosynthetic programs. Trajectory analyses inferred dedifferentiation from the melanocytic toward the neural crest–like state during tumor progression. Comparison with human uveal melanoma revealed commonalities with highly aggressive class 2 uveal melanoma, including gene expression signatures and copy-number gains affecting genes that map to human chromosome 8q beyond the activated MYC allele, suggesting cooperative effects of multiple drivers in this chromosomal region. The tumor microenvironment featured immunosuppressive macrophage populations and exhausted T cells, closely resembling human uveal melanoma. This physiologically relevant, immune-competent model provides a platform for investigating uveal melanoma biology, functionally characterizing candidate driver genes, and developing immune-based therapeutic strategies. Significance:Development of a mouse model resembling the genetic progression and phenotypic plasticity of human uveal melanoma offers an immune-competent preclinical platform for understanding disease immunogenomics and testing immune and targeted treatments.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Uveal melanoma is a highly aggressive intraocular malignancy with limited therapeutic options for metastatic disease. Existing transgenic uveal melanoma mouse models inadequately recapitulate human disease progression, whereas transplant models lack immune competence for studying the tumor immune microenvironment and therapeutic interventions. To address these limitations, we developed a genetically engineered mouse model incorporating stepwise genetic alterations implicated in human uveal melanoma progression. Spatiotemporally controlled expression of mutant GNAQQ209L from the endogenous locus induced choroidal nevi with limited penetrance. Concomitant BAP1 deletion enhanced nevus formation, whereas further MYC activation led to fully penetrant intraocular tumors with the potential to disseminate. Single-cell RNA sequencing revealed that malignant cells segregated into melanocytic and neural crest–like subpopulations characterized by distinct transcriptional and biosynthetic programs. Trajectory analyses inferred dedifferentiation from the melanocytic toward the neural crest–like state during tumor progression. Comparison with human uveal melanoma revealed commonalities with highly aggressive class 2 uveal melanoma, including gene expression signatures and copy-number gains affecting genes that map to human chromosome 8q beyond the activated MYC allele, suggesting cooperative effects of multiple drivers in this chromosomal region. The tumor microenvironment featured immunosuppressive macrophage populations and exhausted T cells, closely resembling human uveal melanoma. This physiologically relevant, immune-competent model provides a platform for investigating uveal melanoma biology, functionally characterizing candidate driver genes, and developing immune-based therapeutic strategies. Significance:Development of a mouse model resembling the genetic progression and phenotypic plasticity of human uveal melanoma offers an immune-competent preclinical platform for understanding disease immunogenomics and testing immune and targeted treatments.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
ScRNA-seq characterization of phenotypic subtypes of malignant cells
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
ScRNA-seq characterization of phenotypic subtypes of malignant cells
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Sequence of primers used for mouse genotyping and cell validation, and sequence of guide RNAs targeting mouse Bap1.
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Sequence of primers used for mouse genotyping and cell validation, and sequence of guide RNAs targeting mouse Bap1.
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Phenotype of GnaqCA; Tyr-CreERT2 mice and validation of Bap1 deletion
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Phenotype of GnaqCA; Tyr-CreERT2 mice and validation of Bap1 deletion
- Open Access
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Expression of MYC and markers of human Class 2 UM
- 4 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma
Expression of MYC and markers of human Class 2 UM